Astellas Pharma Inc (4503.T)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2018||Chairman of the Board, Chairman of the Board of Directors, Representative Director|
|58||2018||President, Chief Executive Officer, Representative Director|
|2018||Senior Executive Officer, Chief Director of Sales|
|2018||Senior Executive Officer, Chief Director of Research|
|2018||Senior Executive Officer, Director of External Affairs|
- Nikkei edges up in choppy trade; weak yen supports exporters
- Nikkei edges higher in choppy trade; weak yen supports exporters
- UPDATE 1-Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study
- CORRECTED-Seattle Genetics, Astellas drug shows rapid tumor shrinkage in advanced bladder cancer study
- Nikkei hits 3-1/2-month low as hopes of early resolution to U.S.-China standoff fade